Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors acting as LDL-lowering agents ...

An article in Cell now describes a germline mutation in proprotein convertase subtilisin/kexin type 9 (PCSK9) that is associated with reduced survival in patients with breast cancer. Inhibition of ...

In the past few years, pharmaceutical companies have produced a class of drugs that lower cholesterol by inhibiting a protein called PCSK9 in a new attempt to reduce the risk of heart disease, the ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

AstraZeneca's take on the PCSK9 inhibitor – an antisense drug licensed from Ionis six years ago – has cleared a proof-of-concept trial in high-risk patients with high blood cholesterol ...